Kenmerk
Optic disc drusen
Optic disc drusen are acellular, calcified deposits within the optic nerve head. Optic disc drusen are congenital and developmental anomalies of the optic nerve head, representing hyaline-containing bodies that, over time, appear as elevated, lumpy irregularities on the anterior portion of the optic nerve.
Samenvatting
- Ook bekend als
- Optic nerve head drusen
- Lichaamssysteem
- Abnormality of the eye
Deze pagina als gegevens
Voeg .json toe aan het adres van de pagina, of vraag application/json aan, om haar als JSON te lezen.
library(jsonlite)
url <- "https://dantelabs.com/traits/optic-disc-drusen.json"
page <- fromJSON(url)
page$trait$nameLees de genen die aan Optic disc drusen gekoppeld zijn, en de rest van uw genoom, met één test.
Vanaf $ 449Gratis verzending · Resultaten binnen 6–8 weken
Mijn Genome Test bestellen119 genen gekoppeld aan Optic disc drusen
Veranderingen in deze genen veroorzaken zeldzame aandoeningen waarbij Optic disc drusen voorkomt. De meeste mensen met dit kenmerk hebben geen van die aandoeningen, en een gen op deze lijst zegt niets over het eigen genoom van iemand.
| Gen | Hoe vaak het voorkomt | Aandoeningen |
|---|---|---|
| IFT172intraflagellar transport 172 | Altijd | In 2 aandoeningen |
| MFRPmembrane frizzled-related protein | Altijd | In 1 aandoening |
| TM2D3TM2 domain containing 3 | Altijd | In 1 aandoening |
| ABCA4ATP binding cassette subfamily A member 4 | Vaak (30–79%) | In 1 aandoening |
| AGBL5AGBL carboxypeptidase 5 | Vaak (30–79%) | In 1 aandoening |
| AHI1Abelson helper integration site 1 | Vaak (30–79%) | In 1 aandoening |
| AHRaryl hydrocarbon receptor | Vaak (30–79%) | In 1 aandoening |
| ALMS1ALMS1 centrosome and basal body associated protein | Vaak (30–79%) | In 2 aandoeningen |
| ARHGEF18Rho/Rac guanine nucleotide exchange factor 18 | Vaak (30–79%) | In 1 aandoening |
| ARL2BPARF like GTPase 2 binding protein | Vaak (30–79%) | In 1 aandoening |
| ARL3ARF like GTPase 3 | Vaak (30–79%) | In 1 aandoening |
| ARL6ARF like GTPase 6 | Vaak (30–79%) | In 1 aandoening |
| BBS1Bardet-Biedl syndrome 1 | Vaak (30–79%) | In 1 aandoening |
| BBS2Bardet-Biedl syndrome 2 | Vaak (30–79%) | In 1 aandoening |
| BEST1bestrophin 1 | Vaak (30–79%) | In 1 aandoening |
| CA4carbonic anhydrase 4 | Vaak (30–79%) | In 1 aandoening |
| CABP4calcium binding protein 4 | Vaak (30–79%) | In 2 aandoeningen |
| CC2D2Acoiled-coil and C2 domain containing 2A | Vaak (30–79%) | In 1 aandoening |
| CDHR1cadherin related family member 1 | Vaak (30–79%) | In 1 aandoening |
| CERKLCERK like autophagy regulator | Vaak (30–79%) | In 1 aandoening |
| CFAP20cilia and flagella associated protein 20 | Vaak (30–79%) | In 1 aandoening |
| CFAP418cilia and flagella associated protein 418 | Vaak (30–79%) | In 1 aandoening |
| CLRN1clarin 1 | Vaak (30–79%) | In 1 aandoening |
| CNGA1cyclic nucleotide gated channel subunit alpha 1 | Vaak (30–79%) | In 1 aandoening |
| CNGB1cyclic nucleotide gated channel subunit beta 1 | Vaak (30–79%) | In 1 aandoening |
| COQ8Bcoenzyme Q8B | Vaak (30–79%) | In 1 aandoening |
| CRB1crumbs cell polarity complex component 1 | Vaak (30–79%) | In 2 aandoeningen |
| CRXcone-rod homeobox | Vaak (30–79%) | In 2 aandoeningen |
| DHDDSdehydrodolichyl diphosphate synthase subunit | Vaak (30–79%) | In 1 aandoening |
| DHX38DEAH-box helicase 38 | Vaak (30–79%) | In 1 aandoening |
| EYSEGF-like photoreceptor maintenance factor | Vaak (30–79%) | In 1 aandoening |
| FAM161AFAM161 centrosomal protein A | Vaak (30–79%) | In 1 aandoening |
| FSCN2fascin actin-bundling protein 2, retinal | Vaak (30–79%) | In 1 aandoening |
| FSD1Lfibronectin type III and SPRY domain containing 1 like | Vaak (30–79%) | In 1 aandoening |
| GUCA1Bguanylate cyclase activator 1B | Vaak (30–79%) | In 1 aandoening |
| HGSNATheparan-alpha-glucosaminide N-acetyltransferase | Vaak (30–79%) | In 1 aandoening |
| HKDC1hexokinase domain containing 1 | Vaak (30–79%) | In 1 aandoening |
| IDH3Aisocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha | Vaak (30–79%) | In 1 aandoening |
| IDH3Bisocitrate dehydrogenase (NAD(+)) 3 non-catalytic subunit beta | Vaak (30–79%) | In 1 aandoening |
| IFT140intraflagellar transport 140 | Vaak (30–79%) | In 2 aandoeningen |
Toon nog 79 genen
| Gen | Hoe vaak het voorkomt | Aandoeningen |
|---|---|---|
| IFT43intraflagellar transport 43 | Vaak (30–79%) | In 1 aandoening |
| IFT88intraflagellar transport 88 | Vaak (30–79%) | In 1 aandoening |
| IMPDH1inosine monophosphate dehydrogenase 1 | Vaak (30–79%) | In 2 aandoeningen |
| IMPG1interphotoreceptor matrix proteoglycan 1 | Vaak (30–79%) | In 1 aandoening |
| IMPG2interphotoreceptor matrix proteoglycan 2 | Vaak (30–79%) | In 1 aandoening |
| KCNJ13potassium inwardly rectifying channel subfamily J member 13 | Vaak (30–79%) | In 2 aandoeningen |
| KIAA1549KIAA1549 | Vaak (30–79%) | In 1 aandoening |
| KIZkizuna centrosomal protein | Vaak (30–79%) | In 1 aandoening |
| KLHL7kelch like family member 7 | Vaak (30–79%) | In 1 aandoening |
| LCA5lebercilin LCA5 | Vaak (30–79%) | In 2 aandoeningen |
| LRATlecithin retinol acyltransferase | Vaak (30–79%) | In 3 aandoeningen |
| MAKmale germ cell associated kinase | Vaak (30–79%) | In 1 aandoening |
| MERTKMER proto-oncogene, tyrosine kinase | Vaak (30–79%) | In 1 aandoening |
| NEK2NIMA related kinase 2 | Vaak (30–79%) | In 1 aandoening |
| NR2E3nuclear receptor subfamily 2 group E member 3 | Vaak (30–79%) | In 1 aandoening |
| NRLneural retina leucine zipper | Vaak (30–79%) | In 1 aandoening |
| OFD1OFD1 centriole and centriolar satellite protein | Vaak (30–79%) | In 1 aandoening |
| OTX2orthodenticle homeobox 2 | Vaak (30–79%) | In 2 aandoeningen |
| PCAREphotoreceptor cilium actin regulator | Vaak (30–79%) | In 1 aandoening |
| PDE6Aphosphodiesterase 6A | Vaak (30–79%) | In 1 aandoening |
| PDE6Bphosphodiesterase 6B | Vaak (30–79%) | In 1 aandoening |
| PDE6Gphosphodiesterase 6G | Vaak (30–79%) | In 1 aandoening |
| POMGNT1protein O-linked mannose N-acetylglucosaminyltransferase 1 (beta 1,2-) | Vaak (30–79%) | In 1 aandoening |
| PRCDphotoreceptor disc component | Vaak (30–79%) | In 1 aandoening |
| PROM1prominin 1 | Vaak (30–79%) | In 1 aandoening |
| PRPF3pre-mRNA processing factor 3 | Vaak (30–79%) | In 1 aandoening |
| PRPF31pre-mRNA processing factor 31 | Vaak (30–79%) | In 1 aandoening |
| PRPF4pre-mRNA splicing tri-snRNP complex factor PRPF4 | Vaak (30–79%) | In 1 aandoening |
| PRPF6pre-mRNA processing factor 6 | Vaak (30–79%) | In 1 aandoening |
| PRPF8pre-mRNA processing factor 8 | Vaak (30–79%) | In 2 aandoeningen |
| PRPH2peripherin 2 | Vaak (30–79%) | In 3 aandoeningen |
| RBP3retinol binding protein 3 | Vaak (30–79%) | In 1 aandoening |
| RDH12retinol dehydrogenase 12 | Vaak (30–79%) | In 2 aandoeningen |
| REEP6receptor accessory protein 6 | Vaak (30–79%) | In 1 aandoening |
| RGRretinal G protein coupled receptor | Vaak (30–79%) | In 1 aandoening |
| RHOrhodopsin | Vaak (30–79%) | In 1 aandoening |
| RLBP1retinaldehyde binding protein 1 | Vaak (30–79%) | In 1 aandoening |
| RNU4-2RNA, U4 small nuclear 2 | Vaak (30–79%) | In 1 aandoening |
| RNU6-1RNA, U6 small nuclear 1 | Vaak (30–79%) | In 1 aandoening |
| RNU6-2RNA, U6 small nuclear 2 | Vaak (30–79%) | In 1 aandoening |
| RNU6-8RNA, U6 small nuclear 8 | Vaak (30–79%) | In 1 aandoening |
| RNU6-9RNA, U6 small nuclear 9 | Vaak (30–79%) | In 1 aandoening |
| ROM1retinal outer segment membrane protein 1 | Vaak (30–79%) | In 1 aandoening |
| RP1RP1 axonemal microtubule associated | Vaak (30–79%) | In 1 aandoening |
| RP1L1RP1 like 1 | Vaak (30–79%) | In 1 aandoening |
| RP2RP2 activator of ARL3 GTPase | Vaak (30–79%) | In 1 aandoening |
| RP9RP9 pre-mRNA splicing factor | Vaak (30–79%) | In 1 aandoening |
| RPE65retinoid isomerohydrolase RPE65 | Vaak (30–79%) | In 3 aandoeningen |
| RPGRretinitis pigmentosa GTPase regulator | Vaak (30–79%) | In 1 aandoening |
| SAGS-antigen visual arrestin | Vaak (30–79%) | In 1 aandoening |
| SAXO6stabilizer of axonemal microtubules 6 | Vaak (30–79%) | In 1 aandoening |
| SCAPERS-phase cyclin A associated protein in the ER | Vaak (30–79%) | In 1 aandoening |
| SEMA4Asemaphorin 4A | Vaak (30–79%) | In 1 aandoening |
| SLC7A14solute carrier family 7 member 14 | Vaak (30–79%) | In 1 aandoening |
| SNRNP200small nuclear ribonucleoprotein U5 subunit 200 | Vaak (30–79%) | In 1 aandoening |
| SPATA7spermatogenesis associated 7 | Vaak (30–79%) | In 3 aandoeningen |
| TMEM216transmembrane protein 216 | Vaak (30–79%) | In 1 aandoening |
| TOPORSTOP1 binding arginine/serine rich protein, E3 ubiquitin ligase | Vaak (30–79%) | In 1 aandoening |
| TTC8tetratricopeptide repeat domain 8 | Vaak (30–79%) | In 1 aandoening |
| TUBTUB bipartite transcription factor | Vaak (30–79%) | In 1 aandoening |
| TULP1TUB like protein 1 | Vaak (30–79%) | In 2 aandoeningen |
| USH2Ausherin | Vaak (30–79%) | In 1 aandoening |
| ZNF408zinc finger protein 408 | Vaak (30–79%) | In 1 aandoening |
| ZNF513zinc finger protein 513 | Vaak (30–79%) | In 1 aandoening |
| AIPL1AIP like 1 HSP90 co-chaperone | Soms (5–29%) | In 1 aandoening |
| CEP290centrosomal protein 290 | Soms (5–29%) | In 1 aandoening |
| GDF6growth differentiation factor 6 | Soms (5–29%) | In 1 aandoening |
| GUCY2Dguanylate cyclase 2D, retinal | Soms (5–29%) | In 2 aandoeningen |
| IQCB1IQ motif containing B1 | Soms (5–29%) | In 1 aandoening |
| NMNAT1nicotinamide nucleotide adenylyltransferase 1 | Soms (5–29%) | In 1 aandoening |
| PCYT1Aphosphate cytidylyltransferase 1A, choline | Soms (5–29%) | In 1 aandoening |
| RD3RD3 regulator of GUCY2D | Soms (5–29%) | In 1 aandoening |
| RPGRIP1RPGR interacting protein 1 | Soms (5–29%) | In 1 aandoening |
| TMEM98transmembrane protein 98 | Soms (5–29%) | In 1 aandoening |
| TUBB4Btubulin beta 4B class IVb | Soms (5–29%) | In 1 aandoening |
| USP45ubiquitin specific peptidase 45 | Soms (5–29%) | In 1 aandoening |
| ABCC6ATP binding cassette subfamily C member 6 | Niet vastgelegd | In 1 aandoening |
| XYLT1xylosyltransferase 1 | Niet vastgelegd | In 1 aandoening |
| XYLT2xylosyltransferase 2 | Niet vastgelegd | In 1 aandoening |
Hoe vaak dit voorkomt bij mensen met een van de aandoeningen van het gen, de hoogste frequentie binnen die aandoeningen, zoals de Human Phenotype Ontology dit vastlegt. Deze pagina's beschrijven kenmerken en het onderzoek erachter; het zijn geen diagnose, en over symptomen kunt u het best een arts of genetisch adviseur raadplegen.
Bredere kenmerken
Waar dit vandaan komt
- De Human Phenotype Ontology, release 2026-09-01: het kenmerk, de namen, de definitie en de genen die ermee verbonden zijn. Meer informatie vindt u op hpo.jax.org.
- Gegevensrelease 2026.10.16-c6eea6bf.
Eén test. Een leven lang antwoorden.
Vanaf $ 449Gratis verzending · Resultaten binnen 6–8 weken